EyePoint Pharmaceuticals is approaching a critical valuation point with upcoming Phase III LUGANO trial results for its DURAVYU treatment targeting wet age-related macular degeneration (AMD), expected by August 2026. The trial focuses on sustained six-month dosing, broad patient inclusion, and direct comparison to the current standard treatment aflibercept, highlighting its potential commercial relevance. EyePoint also owns its manufacturing infrastructure and a drug delivery platform applicable to multiple retinal diseases, strengthening its market position. The company’s cash runway extends through late 2027, but additional funding will be necessary, with positive trial outcomes likely improving fundraising conditions.
The Toro Company reported strong third-quarter results with net sales up 8.4% to $1.23 billion and adjusted EPS of $1.33, beating estimates. Operational efficiency improved, pushing the adjusted operating margin to 13.9%, driven by productivity gains...
KNOT Offshore Partners LP reported strong Q2 2026 results, beating analyst expectations with an EPS of $0.10 versus an estimated loss of $0.03 and revenue of $96.78 million exceeding forecasts. The company maintained a high shuttle tanker fleet utili...
Alphabet CEO Sundar Pichai told employees that Waymo, the company's self-driving car unit, could start making a meaningful financial contribution as soon as 2027. This suggests that Alphabet's investment in autonomous driving technology may be closer...
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
Grant Thornton Switzerland has officially attested the Cardano Foundation's 2025 financial statements directly on the Cardano blockchain, marking the first time a major crypto organization has received an on-chain auditor's signature. This audit, dat...
